UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

The UK’s Medicines and Healthcare products Regulatory Agency said that following global reports of serious adverse events in ...

IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV)Antibody levels remained high after six months in both dose groups, ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined General Meeting (“the Meeting”) to be ...

Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set ...

Saint-Herblain (France), June 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for ...